<menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>
  • Your Good Partner in Biology Research

    Human Cytochrome P450 3A4(CYP3A4) ELISA kit

    • 中文名稱:
      人細胞色素P450 3A4(CYP3A4)ELISA kit
    • 貨號:
      CSB-EL006439HU
    • 規格:
      96T/48T
    • 價格:
      ¥3600/¥2500
    • 其他:

    產品詳情

    • 產品描述:

      This Human CYP3A4 ELISA Kit was designed for the quantitative measurement of Human CYP3A4 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 23.5 pg/mL-1500 pg/mL and the sensitivity is 5.8 pg/mL.

    • 別名:
      CYP3A4; CYP3A3; Cytochrome P450 3A4; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; Albendazole monooxygenase; sulfoxide-forming; Albendazole sulfoxidase; CYPIIIA3; CYPIIIA4; Cholesterol 25-hydroxylase; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase
    • 縮寫:
      CYP3A4
    • Uniprot No.:
    • 種屬:
      Homo sapiens (Human)
    • 樣本類型:
      serum, plasma, tissue homogenates, cell lysates
    • 檢測范圍:
      23.5 pg/mL-1500 pg/mL
    • 靈敏度:
      5.8 pg/mL
    • 反應時間:
      1-5h
    • 樣本體積:
      50-100ul
    • 檢測波長:
      450 nm
    • 研究領域:
      Metabolism
    • 測定原理:
      quantitative
    • 測定方法:
      Sandwich
    • 說明書:
    • 精密度:
      Intra-assay Precision (Precision within an assay): CV%<8%
      Three samples of known concentration were tested twenty times on one plate to assess.
      Inter-assay Precision (Precision between assays): CV%<10%
      Three samples of known concentration were tested in twenty assays to assess.
    • 線性度:
      To assess the linearity of the assay, samples were spiked with high concentrations of human CYP3A4 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
       SampleSerum(n=4)
      1:1Average %90
      Range %85-99
      1:2Average %96
      Range %90-102
      1:4Average %97
      Range %89-105
      1:5Average %95
      Range %90-100
    • 回收率:
      The recovery of human CYP3A4 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
      Sample TypeAverage % RecoveryRange
      Serum (n=5) 9894-103
      EDTA plasma (n=4)9895-100
    • 標準曲線:
      These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
      pg/mlOD1OD2AverageCorrected
      15002.754 2.791 2.773 2.597
      7502.369 2.394 2.382 2.206
      3751.824 1.789 1.807 1.631
      187.51.057 1.082 1.070 0.894
      940.640 0.647 0.644 0.468
      470.435 0.465 0.450 0.274
      23.50.264 0.278 0.271 0.095
      00.175 0.176 0.176  
    • 數據處理:
    • 貨期:
      3-5 working days

    產品評價

    靶點詳情

    • 功能:
      A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds. Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position. Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone. Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones. Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis. Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond. Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling. Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance. Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole. Hydroxylates antimalarial drug quinine. Acts as a 1,4-cineole 2-exo-monooxygenase. Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)).
    • 基因功能參考文獻:
      1. Experimental in silico and in vivo studies confirmed that the original Russian benzodiazepine phenazepam was the substrate of CYP3A4 isoenzyme. PMID: 29727298
      2. Apigenin showed reversible inhibition, acacetin, and chrysin showed combined irreversible and reversible inhibition while chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin showed pure irreversible inhibition. These results alert on possible flavonoiddrug interactions on the level of CYP3A4 PMID: 30301254
      3. This patient should be regarded as a CYP3A-poor metabolizer. PMID: 29469606
      4. spectroscopic studies clarified the heteroactivation of CYP3A4 caused by efavirenz with a proper affinity to the peripheral site PMID: 29191071
      5. The genetic polymorphisms of the multi-drug resistance-1 (MDR-1) and human cytochrome P450 3A (CYP3A4 and CYP3A5) genes were analyzed and compared between steroid sensitive, steroid resistant and control groups. PMID: 30143489
      6. this meta-analysis suggests that the CYP3A4*1B polymorphism might play a modest role in susceptibility to cancer, especially for leukemia. PMID: 30143500
      7. JNK is a novel mechanistic regulator of CYP3A4 induction by PXR. PMID: 29440179
      8. The other four metabolites were almost exclusively metabolized by CYP3A4. PMID: 29475834
      9. It observed an increase in the activity of CYP3A following but not during pregnancy when measured using the 4beta-hydroxycholesterol/cholesterol ratio. In addition, based on our results, it suggestes that the plasma 4beta-hydroxycholesterol/cholesterol ratio be used to measure CYP3A activity in pregnant women. PMID: 29759884
      10. These findings also suggest that EGF may be an important regulator of CYP3A4 expression in vivo. PMID: 29189189
      11. our results indicate that a significant level of MDR1 mRNA, but not CYP3A4 mRNA, is intrinsically present before chemotherapy in advanced STS tumors. PMID: 29689707
      12. A weak-to-moderate CYP3A4 induction by midostaurin. PMID: 29117990
      13. CYP3A4 *18B and GCK G-30A polymorphisms were related to new-onset diabetes after transplantation (p < 0.05). The lower concentration/dose or fasting serum glucose was in CYP3A4 *1/*1 carriers than that in *18B/*18B carriers in all the renal transplant recipients (p < 0.05), respectively. PMID: 29546446
      14. Data suggest high similarity in mechanisms involved in regulation of expression of pig CYP3A29 and human CYP3A4 in hepatocytes. PMID: 30153482
      15. rs7668282 (UGT2B7, T>C) was more prevalent in sodium valproate (VPA)-resistant patients than drug-responsive patients. rs2242480 (CYP3A4, C>T) and rs10188577 (SCN1A, T>C) were more prevalent in drug-responsive patients compared to drug-resistant patients. In children with generalized seizures on VPA therapy, polymorphisms of UGT2B7, CYP3A4, and SCN1A genes were associated with seizure reduction. PMID: 29679912
      16. There were no significant differences in the bosutinib C0 between genotypes for ABCB1, ABCG2, and CYP3A4 polymorphisms. PMID: 29736778
      17. These results suggest that human and marmoset P450 3A4/90 and 4F12 in livers or small intestines played important roles in terfenadine t-butyl hydroxylation. Marmosets could be a model for humans during first pass extraction of terfenadine and related substrates. PMID: 28436281
      18. This first description of CYP3A4*20 null genotype in liver-transplanted patients, supports the relevance of CYP3A genotyping in tacrolimus therapy PMID: 29256966
      19. We demonstrate for the first time that the effect of ABCB1 diplotype on tacrolimus disposition is dependent on both CYP3A5 and CYP3A4 genotype. PMID: 27378609
      20. Some flavonoids exhibit selective inhibition toward CYP3A4 rather than other major cytochromes. Here, data suggest high risk of herb-drug interactions or food-drug interactions could be caused by flavonoids; vital structural elements of natural flavonoids could lead to interactions with clinical drugs normally eliminated via CYP3A4 metabolism. PMID: 29753067
      21. The mAb concomitantly shifted IL-1beta IC50 values towards CYP3A4 activity. PMID: 28260174
      22. CYP3A4 was identified as a novel tumor suppressor gene related to a poor prognosis in HCC. PMID: 29109094
      23. In CYP3A4, the most energetically favorable docking mode places testosterone in a position with the methyl groups directed toward the heme iron PMID: 28986474
      24. this study indicates that CYP3A activity is regained subsequent to kidney transplantation PMID: 28928137
      25. Younger age, POR*28 allele, and CYP3A5*3 allele were associated with higher cyclosporine dosing requirements and lower concentration/dose ratio. PMID: 29135906
      26. Single nucleotide polymorphism rs4646437 in CYP3A4 at 7q21.1 (p = .0325), associated with alpha-adrenergic receptor antagonist drug effect in Benign Prostatic Hyperplasia. PMID: 28787260
      27. CYP3A4*1B is associated with CsA C0/Dose ratio in renal transplant recipients which indicates patients with CYP3A4*1B allele require lower dose of CsA to reach target blood concentration compared with the CYP3A4*1 carriers.[meta-analysis] PMID: 29678659
      28. The MDR1/CYP3A4/OPRM1 gene polymorphisms influenced the fentanyl consumption and the physiological effects of intravenous analgesia in the Chinese women who received lower segment caesarean section surgeries. PMID: 29601950
      29. Molecular dynamics simulations reveal significantly different modes of interactions of DND and ARVL with the substrate binding pocket and with a peripheral allosteric site. Interactions of both substrates with residues F213 and F219 at the allosteric site play a critical role in the communication of conformational changes induced by effector binding to productive binding of the substrate at the catalytic site. PMID: 29200287
      30. The results of this study suggested that the Prospective assaying of CYP3A-status (CYP3A4 expression, CYP3A5 genotype) may better identify the Alzheimer patients with higher risk of inefficiency or adverse reactions and may facilitate the improvement of personalized clozapine therapy PMID: 28340122
      31. In oral contraceptive users, haplotype A and B in the CYP3A4 gene were associated with venous thrombosis risk, but not in non-users; however, the effect on Sex-hormone-binding-globulin levels was not directional with the risk. PMID: 28579309
      32. The combined CYP3A4 and CYP3A5 genotype of renal transplant recipients has a major influence on the Tacrolimus dose required to reach the target exposure. PMID: 28704257
      33. We solved the 2.7 A crystal structure of the CYP3A4-midazolam (MDZ) complex, where the drug is well defined and oriented suitably for hydroxylation of the C1 atom, the major site of metabolism. This binding mode requires H-bonding to Ser119 and a dramatic conformational switch in the F-G fragment, which transmits to the adjacent helices, resulting in a collapse of the active site cavity and MDZ immobilization. PMID: 28031486
      34. Our results provide information on CYP3A4 polymorphisms in Tibetan individuals which may help to optimize pharmacotherapy effectiveness by providing personalized medicine to this ethnic group. PMID: 28674221
      35. Among two SNPs in CYP3A4 and CYP3A5 and 12 SNPs in ABCB1 gene, an association with ovarian cancer risk was observed for ABCB1 rs2157926 SNP only. PMID: 29491071
      36. Low CYP3A4 Activity is associated with Crohn's Disease. PMID: 28301431
      37. Cryopreserved human hepatocytes can be stored stably for more than a decade with little or no change in CYP3A4/5 induction. PMID: 28411281
      38. Associations between SLCO1B1 521C and cholesterol response were not detected in African Americans (n = 333). Associations between CYP3A4*22 or CYP3A5*3 and cholesterol response were not detected in whites or African Americans. PMID: 28482130
      39. This kdeg value for CYP3A4 was in good agreement with recently reported values. PMID: 28289057
      40. Sorafenib was poorly tolerated, and anti-Kaposi sarcoma (KS)activity was modest. Strong CYP3A4 inhibitors may contribute to sorafenib toxicity, and ritonavir has previously been shown to be a CYP3A4 inhibitor. Alternate antiretroviral agents without predicted interactions should be used when possible for concurrent administration with sorafenib PMID: 28341759
      41. A total of 84.8% of our patients were found to express both the CYP3capital A, Cyrillic5*3*3 genotype and CYP3capital A, Cyrillic4*1*1/*1*1B. Further studies are necessary in order to show the influence of these genetic polymorphisms on tacrolimus blood concentrations. PMID: 29314799
      42. This study has identified 4 synonymous variants in the HCN4 gene and 3 SNPs in the CYP3A4 gene. None of the variants appear to have a major effect on the reduction of HR produced by ivabradine. PMID: 27439367
      43. Methylation status of cytosine in the CYP3A4 proximal promoter correlated with changes in developmental expression of mRNA. PMID: 26772622
      44. Occupancy by modified histones was consistent with chromatin structural changes contributing to the mechanisms regulating CYP3A4 ontogeny. PMID: 26921389
      45. Hydroxyl metabolite (M3) of VX-509 which is formed via the aldehyde oxidase pathway is responsible for CYP3A4 inhibition. PMID: 27298338
      46. CYP3A5 genotype has minimal impact on the probability of quetiapine target attainment of the 1-hour concentrations but a significant impact on the 12-hour concentrations. PMID: 27137148
      47. CYP3A4 expression and N-acetyl transferase 2 acetylator phenotype can better identify the patients with higher risk of adverse reactions and can facilitate the improvement of personalized clonazepam therapy and withdrawal regimen. PMID: 27639091
      48. The dose-dependent FaFg of selective and dual CYP3A and/or P-gp substrates was well predicted. PMID: 27538919
      49. The magnitude of drug-drug interactions (DDIs) for studies with rifampicin and seven CYP3A4 probe substrates. PMID: 27026679
      50. This finding equated to lower cytochrome P450 isoform 3A4 (CYP3A4) EC50 values in the HepatoPac system. PMID: 27655038

      顯示更多

      收起更多

    • 亞細胞定位:
      Endoplasmic reticulum membrane; Single-pass membrane protein. Microsome membrane; Single-pass membrane protein.
    • 蛋白家族:
      Cytochrome P450 family
    • 組織特異性:
      Expressed in prostate and liver. According to some authors, it is not expressed in brain. According to others, weak levels of expression are measured in some brain locations. Also expressed in epithelium of the small intestine and large intestine, bile du
    • 數據庫鏈接:

      HGNC: 2637

      OMIM: 124010

      KEGG: hsa:1576

      STRING: 9606.ENSP00000337915

      UniGene: Hs.728751



    1v1周青梅郑宣木天寥
    <menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>
  • <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>
    <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>